Cost effectiveness of adalimumab in the treatment of patients with moderate to severe rheumatoid arthritis in Sweden.

@article{Bansback2005CostEO,
  title={Cost effectiveness of adalimumab in the treatment of patients with moderate to severe rheumatoid arthritis in Sweden.},
  author={N. Bansback and A. Brennan and O. Ghatnekar},
  journal={Annals of the rheumatic diseases},
  year={2005},
  volume={64 7},
  pages={
          995-1002
        }
}
BACKGROUND Societal decision makers increasingly emphasise their need for evidence based economic analyses to make reimbursement decisions. OBJECTIVE To analyse the cost utility of adalimumab, on both incremental cost and incremental quality adjusted life years (QALYs), versus traditional disease modifying antirheumatic drugs and the other tumour necrosis factor (TNF) antagonists suitable for submission to the Swedish LFN (Pharmaceutical Benefit Board). METHODS Swedish unit costs and… Expand
119 Citations
Cost-effectiveness of adalimumab for rheumatoid arthritis in Germany
  • 7
  • PDF
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 50 REFERENCES
A multicenter cost-of-illness study on rheumatoid arthritis in Italy.
  • 105
The epidemiology of drug treatment failure in rheumatoid arthritis.
  • F. Wolfe
  • Medicine
  • Bailliere's clinical rheumatology
  • 1995
  • 134
...
1
2
3
4
5
...